Neurologic complications |
Ischemic stroke | 3/26 (11.5) | 1/10 (10.0) | 2/16 (12.5) |
Intracranial hemorrhage | 6/26 (23.1) | 0 | 6/16 (37.5) |
Thrombotic complications and therapies |
Deep venous thrombosis on ultrasonography | 2/13 (15.4) | 0 | 2/9 (22.2) |
Pulmonary embolism on CTPA | 6/26 (23.1) | 3/12 (25.0) | 3/14 (21.4) |
Received therapeutic anticoagulation | 11/100 (11.0) | 3/68 (4.4) | 8/32 (25.0) |
Started for presumed hypercoagulable state from COVID-19 | 3/100 (3.0) | 0 | 3/32 (9.4) |
Started for confirmed venous thromboembolism | 7/100 (7.0) | 3/68 (4.4) | 4/32 (12.5) |
Started for VV-ECMO circuit | 1/100 (1.0) | 0 | 1/32 (3.1) |
Cardiac and hemodynamic complications and therapies |
Received vasopressors or inotropes | NA | NA | 24/32 (75.0) |
Duration of vasopressors or inotropes, d, median (IQR) | NA | NA | n = 24 9 (3.75–11.75) |
Corticosteroids for hemodynamic shock | 4/100 (4.0) | 0 | 4/32 (12.5) |
Echocardiography findings† |
Depressed LVEF (30%–50%) | 2/29 (6.9) | 0/5 (0) | 2/24 (8.3) |
Severely depressed LVEF (< 30%) | 2/29 (6.9) | 1/5 (20.0) | 1/24 (4.2) |
Reduced RV systolic function | 5/29 (17.2) | 1/5 (20.0) | 3/24 (12.5) |
Pulmonary hypertension | 9/29 (31.0) | 2/5 (40.0) | 7/24 (29.2) |
Pericardial effusion | 1/29 (3.4) | 0/5 (0) | 1/24 (4.2) |
Renal complications and therapies |
Acute kidney injury‡ | 27/100 (27.0) | 11/68 (16.2) | 16/32 (50.0) |
Received CRRT | NA | NA | 5/32 (15.6) |
Duration of CRRT, median (IQR) | NA | NA | 4 (2.0–6.5) |
Highest AKIN stage |
Stage I | 16/100 (16.0) | 9/68 (13.2) | 7/32 (21.9) |
Stage II | 5/100 (5.0) | 0 | 5/32 (15.6) |
Stage III | 6/100 (6.0) | 2/68 (2.9) | 4/32 (12.5) |
Secondary infections |
Positive respiratory culture (bacterial or fungal) | 13/100 (13.0) | 0 | 13/32 (40.6) |
Positive blood culture | 8/100 (8.0) | 2/68 (2.9) | 6/32 (18.8) |
Positive urine culture | 15/100 (15.0) | 4/68 (5.9) | 11/32 (34.4) |
Clostridioides difficile | 1/100 (1.0) | 1/68 (1.5) | 0 |